Approach

Summary

Licensing status

Publication and contact information

Drug delivery

Fc fragment of IgG receptor transporter-a (FCGRT; FCRN)-targeted nanoparticles for oral nanoparticle delivery

In vitro and mouse studies suggest FCRN-targeted nanoparticles could be used for oral drug delivery. Polylactic acid (PLA)-polyethylene glycol (PEG) nanoparticles with an IgG Fc fragment conjugated to the PEG shell had increased transport across a human epithelial colorectal adenocarcinoma monolayer and across the intestinal epithelium in mice compared with untargeted controls. In fasted mice, oral Fcrn-targeted nanoparticles encapsulating insulin caused a hypoglycemic response that lasted longer than injection of free insulin, whereas oral delivery of untargeted nanoparticles had no effect. Next steps include testing whether the nanoparticle platform can be used for delivery across other biological barriers (see Oral nanoparticles, page 1).

SciBX 6(48); doi:10.1038/scibx.2013.1406
Published online Dec. 19, 2013

Patent application filed; available for licensing

Pridgen, E.M. et al. Sci. Transl. Med.; published online Nov. 27, 2013;
doi:10.1126/scitranslmed.3007049
Contact: Omid C. Farokhzad, Brigham and Women's Hospital, Boston, Mass.
e-mail:
ofarokhzad@zeus.bwh.harvard.edu
Contact: Frank Alexis, Harvard Medical School, Boston, Mass.
e-mail:
falexis@clemson.edu
Contact: Rohit Karnik, Massachusetts Institute of Technology, Cambridge, Mass.
e-mail:
karnik@mit.edu